Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer News, features, and commentary about cancer-related issues Nov 01, 2024
Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer News, features, and commentary about cancer-related issues Oct 25, 2024
Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma High overall response rate, even though many were ineligible for trial leading to drug's approval Oct 04, 2024
Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer News, features, and commentary about cancer-related issues Oct 04, 2024
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement News, features, and commentary about cancer-related issues Sep 26, 2024
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments Incidence almost identical to that with standard cancer treatment in randomized trials Sep 11, 2024
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers Systematic review and meta-analysis finds CAR T-cell-specific toxicities only account for 11.5% Sep 04, 2024
Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants Better survival in one registry study, detriment with class I HLA mismatch in another Aug 27, 2024
Alarm Over Pharma-China Link; Taking Screening to the People; Agriculture and Cancer News, features, and commentary about cancer-related issues Aug 23, 2024
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer News, features, and commentary about cancer-related issues Aug 16, 2024
No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire News, features, and commentary about cancer-related issues Aug 09, 2024
FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma Indicated for newly diagnosed patients who are eligible for stem cell transplant Jul 31, 2024
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy A third of patients who had received multiple prior lines of therapy responded, small study shows Jul 10, 2024
Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT News, features, and commentary about cancer-related issues Jul 05, 2024
Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma Joseph Mikhael, MD, leads a discussion on the DREAMM-7 and DREAMM-8 trials Jul 05, 2024 video
CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma Joseph Mikhael, MD, leads a discussion on the subgroup analysis of CARTITUDE-4 Jun 27, 2024 video
Real-World Analysis Identifies Meds Tied to Higher Risk of Liver Injury Case reports may not be as reliable, researchers say Jun 25, 2024
Using MRD Status to Deescalate Multiple Myeloma Therapy Joseph Mikhael, MD, leads a discussion on the findings of the MRD2STOP study Jun 20, 2024 video
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma Joseph Mikhael, MD, leads a roundtable discussion on two positive phase III trials from ASCO Jun 14, 2024 video
Adding Isatuximab to Standard Backbone Improves Outcomes in Multiple Myeloma Two trials show positive outcomes Jun 04, 2024
Industry Clinic β’ Ad Insights What Will It Take to Deliver Both Health & Care in Oncology? Jun 04, 2024
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma Second belantamab mafodotin-containing triplet to show potency in this setting Jun 02, 2024
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise News, features, and commentary about cancer-related issues May 10, 2024
Ending Oncology's Toxic Relationship With High Chemotherapy Doses Optimizing doses can improve patient outcomes and lower costs May 10, 2024
Quadruplet Shows 'Excellent Activity' in Myeloma Patients Who Defer HSCT ORR reaches 90% with isatuximab plus KRd in newly diagnosed disease Apr 26, 2024
FDA Approves Earlier Use of CAR-T Products for Myeloma Carvykti and Abecma move to second- and third-line, respectively Apr 08, 2024
High Response Rate in R/R Multiple Myeloma With Bispecific Antibody ORR of 71% that deepened over time and favorable safety profile with linvoseltamab Apr 08, 2024
Chemo and Heart Disease; Flawed Lung Cancer Screening; New Vax Recommendations News, features, and commentary about cancer-related issues Mar 29, 2024
FDA Panel Gives Thumbs Up to Earlier Use of CAR T-Cell Therapy in Multiple Myeloma Cilta-cel, ide-cel win support despite concerns about early mortality risk Mar 16, 2024
Early Death Risk Muddies Risk-Benefit Assessment of CAR-T Therapies for Myeloma FDA advisory panel to weigh the evidence for cilta-cel, ide-cel in day-long meeting Mar 14, 2024
A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu News, features, and commentary about cancer-related issues Mar 07, 2024
Toxic Gas That Sterilizes Medical Devices Prompts Safety Rule Update The EPA is set to take action after public outcry Mar 03, 2024
Taking Control of the Cancer Journey Kathy Giusti gives patients and healthcare workers advice for navigating cancer treatment Mar 02, 2024 podcast
Amy Schumer's Diagnosis; FDA Yanks Cancer Drug; Nursing Student Murdered Health news and commentary from around the Web gathered by ΒιΆΉ΄«Γ½ staff Feb 26, 2024
Transforming Shots Into Pills; 'Tip of the Iceberg' for TILs? Food Additives Warning News, features, and commentary about cancer-related issues Feb 23, 2024
Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma No PFS benefit from adding the monoclonal antibody to standard therapy Feb 20, 2024
Pulled Myeloma Drug May Have a Role in Treating the Disease After All Belantamab mafodotin boosts PFS by nearly 2 years when combined with bortezomib, dexamethasone Feb 07, 2024
When a Revolutionary Cancer Treatment Causes Cancer The potential benefits of CAR T-cell therapies still far outweigh the risks Jan 27, 2024
How Can Cancer Risk Be Cut in Communities Exposed to Toxins? Group outlines plan to bring the latest testing and treatment to medically underserved minorities Jan 25, 2024
CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning Post-treatment cases grow to 22 since products' initial approvals Jan 24, 2024
